These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
138 related items for PubMed ID: 7986110
1. [Present strategy for new drug development in the USA]. Shimada Y. Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():315-24. PubMed ID: 7986110 [Abstract] [Full Text] [Related]
4. The preclinical new drug research program of the National Cancer Institute. Driscoll JS. Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438 [Abstract] [Full Text] [Related]
5. Investigational trials of anticancer drugs: establishing safeguards for experimentation. Chabner BA, Wittes R, Hoth D, Hubbard S. Public Health Rep; 1984 Jan; 99(4):355-60. PubMed ID: 6431482 [Abstract] [Full Text] [Related]
6. Japan works to shorten "drug lag," boost trials of new drugs. Sinha G. J Natl Cancer Inst; 2010 Feb 03; 102(3):148-51. PubMed ID: 20107160 [No Abstract] [Full Text] [Related]
7. Proceedings: Anticancer drug development programs: a comparison of approaches in the United States, the Soviet Union, Japan, and Western Europe. Carter SK. Natl Cancer Inst Monogr; 1974 Feb 03; 40():31-45. PubMed ID: 4819407 [No Abstract] [Full Text] [Related]
8. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute. Christian MC, Pluda JM, Ho PT, Arbuck SG, Murgo AJ, Sausville EA. Semin Oncol; 1997 Apr 03; 24(2):219-40. PubMed ID: 9129691 [Abstract] [Full Text] [Related]
11. Clinical development of anticancer agents--a National Cancer Institute perspective. Marsoni S, Wittes R. Cancer Treat Rep; 1984 Jan 03; 68(1):77-85. PubMed ID: 6362870 [No Abstract] [Full Text] [Related]
13. European collaboration in trials of new agents for children with cancer. Ablett S, Doz F, Morland B, Vassal G, New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG), Pharmacology Group of the French Society of Paediatric Oncology (SFOP). Eur J Cancer; 2004 Aug 03; 40(12):1886-92. PubMed ID: 15288291 [Abstract] [Full Text] [Related]
14. The role of the National Cancer Institute in drug development. Doroshow J. Clin Adv Hematol Oncol; 2005 Apr 03; 3(4):257-8. PubMed ID: 16166997 [No Abstract] [Full Text] [Related]
16. [Impact of rapid advancement of international standardization on technical requirements for new drug registration]. Kurokawa T. Gan To Kagaku Ryoho; 1996 Apr 03; 23(5):509-16. PubMed ID: 8678507 [Abstract] [Full Text] [Related]
17. Commentary on "European collaboration in trials of new agents for children with cancer" by Ablett et al. Smith MA, Anderson BD. Eur J Cancer; 2004 Aug 03; 40(12):1893-5. PubMed ID: 15288292 [Abstract] [Full Text] [Related]
18. Lessons learned from independent central review. Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J. Eur J Cancer; 2009 Jan 03; 45(2):268-74. PubMed ID: 19101138 [Abstract] [Full Text] [Related]
19. Closing Remarks. Reed E. Oncologist; 1996 Jan 03; 1(4):276-277. PubMed ID: 10388002 [Abstract] [Full Text] [Related]
20. [Ethical principles in preclinical and clinical experimentation on new drugs, with special reference to biological products]. Pérez Miravete A. Salud Publica Mex; 1986 Jan 03; 28(4):443-56. PubMed ID: 3775534 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]